Association of body mass index with removal of etonogestrel subdermal implant

Petra M. Casey, Margaret E. Long, Mary L. Marnach, Jennifer Fleming-Harvey, Linda B. Drozdowicz, Amy L. Weaver

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Background: Bleeding irregularities represent the most common etonogestrel subdermal implant (ESI) removal indication. Study Design: ESI placements (n= 304) from June 2007 to April 2011 were grouped by removal indications. Group characteristics were compared using one-way analysis of variance, Kruskal-Wallis and χ2 test. Results: Of 304 insertions, 30.6% reported irregular bleeding. Removal indications included bleeding (Group 1, n= 50), side effects (Group 2, n= 17) and desired pregnancy/no need (Group 3, n= 25). Group 4 kept (n= 198) or reinserted (n= 14) ESI. Median body mass index was lower for Group 1 compared to other groups (p=.012). Group 3 was older than Group 1 or 4 (p=.021), and more likely parous (p<.001) and postpartum (p=.001) than other groups. Lactational placement was more common in Group 3 than 4 (p<.001). Obese women were 2.6 times less likely to remove ESI for bleeding vs. normal-weight or overweight women (95% confidence interval, 1.2-5.7; p=.014). Conclusions: After adjusting for age and parity, obese women were less likely to have ESI removal for bleeding.

Original languageEnglish (US)
Pages (from-to)370-374
Number of pages5
Issue number3
StatePublished - Mar 1 2013


  • Contraceptive implant
  • Contraceptive implant removal
  • Etonogestrel subdermal implant
  • Irregular bleeding vaginal bleeding

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology


Dive into the research topics of 'Association of body mass index with removal of etonogestrel subdermal implant'. Together they form a unique fingerprint.

Cite this